एट्राविरिन के इंटरैक्शन

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (आइवाब्राडिन लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (इरिनोटेकन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (उपाडासिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (उब्रोजेपेंट लेबल, दवाओं के इंटरैक्शन)

Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ] . (एंटेकाविर लेबल, बॉक्स्ड चेतावनी)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (एकालाब्रुटिनिब लेबल, दवाओं के इंटरैक्शन)

Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible. (एक्सिटिनिब लेबल, दवाओं के इंटरैक्शन)

Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5. (एडेफोविर लेबल, बॉक्स्ड चेतावनी)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (एपिक्साबैन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (एप्रेमिलास्ट लेबल, चेतावनियां और सावधानियां)

Lactic Acidosis and Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals. (एफाविरेंज़, लैमिवुडिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (एबिराटेरोन लेबल, दवाओं के इंटरैक्शन)

Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, alone or in combination with other antiretrovirals. (एमट्रिसिटाबिन लेबल, चेतावनियां और सावधानियां)

Etravirine and delavirdine should not be co-administered. rilpivirine ↓ rilpivirine ↔ etravirine Combining two NNRTIs has not been shown to be beneficial. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (एल्पेलिसिब लेबल, दवाओं के इंटरैक्शन)

Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Therefore, administration of potent enzyme inducers of CYP3A4 with ketoconazole tablets is not recommended. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (कैबोज़ैंटिनिब लेबल, दवाओं के इंटरैक्शन)

Coadministration with other antiretroviral medications for PrEP is not recommended. (कैबोटेग्राविर लेबल, दवाओं के इंटरैक्शन)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (कैरिप्राज़िन लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (कोडीन लेबल, बॉक्स्ड चेतावनी)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (कोल्चिसिन लेबल, दवाओं के इंटरैक्शन)

Antiviral and antiretroviral drugs: Avoid concomitant use. (क्लैड्रिबिन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (ज़िडोवुडिन लेबल, बॉक्स्ड चेतावनी)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (ज़ोल्पिडेम लेबल, दवाओं के इंटरैक्शन)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (टिकाग्रेलोर लेबल, दवाओं के इंटरैक्शन)

Lactic Acidosis/Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including TDF, alone or in combination with other antiretrovirals. (टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (टैलाज़ोपैरिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (टैसिमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (टोपोटेकन लेबल, दवाओं के इंटरैक्शन)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use with strong CYP3A inducers if possible. (ट्रेटिनोइन लेबल, दवाओं के इंटरैक्शन)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (ट्रैबेक्टेडिन लेबल, दवाओं के इंटरैक्शन)

…atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure (AUC) of etravirine was reduced when Etravirine was co-administered with darunavir/ritonavir. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (डासाटिनिब लेबल, दवाओं के इंटरैक्शन)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (डेफ्लाज़ाकॉर्ट लेबल, दवाओं के इंटरैक्शन)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (डैबिगैट्रान लेबल, चेतावनियां और सावधानियां)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (डैरिडोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (डॉक्सोरूबिसिन लेबल, दवाओं के इंटरैक्शन)

HIV Antiviral Agents efavirenz etravirine nevirapine ↓ doravirine Use with efavirenz, etravirine, or nevirapine is not recommended. (डोराविरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Drug Class: Drug Name Effect on Concentration of Dolutegravir and/or Concomitant Drug Clinical Comment HIV-1 Antiviral Agents Non-nucleoside reverse transcriptase inhibitor: Etravirine a ↓Dolutegravir Use of TIVICAY or TIVICAY PD with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended. (डोलुटेग्राविर लेबल, दवाओं के इंटरैक्शन)

• CYP3A inducers: Avoid concomitant use. (ड्रोनेडेरोन लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (थायोटेपा लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (नालोक्सेगोल लेबल, दवाओं के इंटरैक्शन)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

HIV-antiviral agents: protease inhibitors (PIs) atazanavir (without ritonavir) ↓ atazanavir Co-administration of Etravirine and atazanavir without low-dose ritonavir is not recommended. atazanavir/ritonavir ↓ atazanavir ↔ etravirine Concomitant use of Etravirine with atazanavir/ritonavir decreased atazanavir C min but it is not considered clinically relevant. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (निलोटिनिब लेबल, दवाओं के इंटरैक्शन)

Female gender and higher CD4 + cell counts at initiation of therapy place patients at increased risk; women with CD4 + cell counts greater than 250 cells/mm 3 , including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. (नेविरापिन लेबल, बॉक्स्ड चेतावनी)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (नॉरएथिस्टेरोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (पाल्बोसिक्लिब लेबल, दवाओं के इंटरैक्शन)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (पिमावैनसेरिन लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (पैलिपेरिडोन लेबल, दवाओं के इंटरैक्शन)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (प्राज़िक्वांटेल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

…unknown Co-administration of Etravirine with darunavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir. fosamprenavir (without ritonavir) ↑ amprenavir Concomitant use of Etravirine with fosamprenavir without low-dose ritonavir may cause a significant alteration in the plasma concentration… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (फ्लिबैनसेरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A4 Inducers: Avoid concomitant use. (बोर्टेज़ोमिब लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (बोसुटिनिब लेबल, दवाओं के इंटरैक्शन)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (बोसेंटन लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

CYP3A inducers: Do not use mifepristone with CYP3A inducers ( 7.3 ). (मिफेप्रिस्टोन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (मैसिटेंटन लेबल, दवाओं के इंटरैक्शन)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (यूलिप्रिस्टल लेबल, चेतावनियां और सावधानियां)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (रिटलेसिटिनिब लेबल, दवाओं के इंटरैक्शन)

Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Etravirine should not be used with rifampin or rifapentine as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

If Etravirine is co-administered with darunavir/ritonavir, lopinavir/ritonavir or saquinavir/ritonavir, then rifabutin should not be co-administered due to the potential for significant reductions in etravirine exposure. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Etravirine should not be used with rifampin or rifapentine as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (रिमेजेपेंट लेबल, दवाओं के इंटरैक्शन)

Etravirine and delavirdine should not be co-administered. rilpivirine ↓ rilpivirine ↔ etravirine Combining two NNRTIs has not been shown to be beneficial. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (रिवारोक्साबैन लेबल, चेतावनियां और सावधानियां)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (रैनोलाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (रोफ्लुमिलास्ट लेबल, चेतावनियां और सावधानियां)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (रोमिडेप्सिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (रोलापिटेंट लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (लुमाटेपेरोन लेबल, दवाओं के इंटरैक्शन)

Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. (लेडिपासविर और सोफोसबुविर लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1) ] . (लेनाकैपाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (लैरोट्रेक्टिनिब लेबल, दवाओं के इंटरैक्शन)

Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments. atazanavir/cobicistat ↓ atazanavir ↓ cobicistat Co-administration of Etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir. darunavir/ritonavir ↓ etravirine The mean systemic exposure… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (लोरलाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (ल्यूरासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (वाल्बेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (विन्क्रिस्टिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (वेपडेजेस्ट्रेंट लेबल, दवाओं के इंटरैक्शन)

Avoid use of Citalopram Capsules in CYP2C19 poor metabolizers, patients receiving concomitant cimetidine or another CYP2C19 inhibitor, patients with hepatic impairment, and patients who are greater than 60 years of age, because Citalopram Capsules are only available in a 30 mg dose strength and dosage adjustments are not possible [see Drug Interactions ( 7 ),… (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (सिरोलिमस लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट HIV की कुछ दवाओं का खून में स्तर इतना घटा सकता है कि इलाज विफल हो जाए। (NCCIH, St. John's Wort)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (सोराफेनिब लेबल, दवाओं के इंटरैक्शन)

Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. (हाइड्रॉक्सीयूरिया लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (अफाटिनिब लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (आइफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antifungals : fluconazole ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant systemic use of itraconazole or ketoconazole and Etravirine may increase plasma concentrations of etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (इमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (एक्सेमेस्टेन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

…ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir]) /HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., efavirenz, nevirapine] or increase [e.g., etravirine]). (एटोनोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Etravirine with efavirenz or nevirapine may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (एम्लोडिपिन और ओल्मेसार्टन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ] . (एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (एस्ज़ोपिक्लोन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive efficacy. (एस्ट्राडियोल और डायनोजेस्ट लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (एस्लिकार्बाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (ऑर्लिस्टैट लेबल, चेतावनियां और सावधानियां)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (ओन्डैनसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )]. (ओमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Strong inducer of CYP3A4 or CYP2C19: Consider dose increase of EPIDIOLEX. (कैनाबिडियोल (प्रिस्क्रिप्शन दवा) लेबल, दवाओं के इंटरैक्शन)

Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. (कैरिसोप्रोडोल लेबल, दवाओं के इंटरैक्शन)

Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin acetate for injection is expected to reduce the plasma concentrations of caspofungin acetate for injection. (कैस्पोफंगिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (क्लिंडामाइसिन लेबल, दवाओं के इंटरैक्शन)

Antiinfective : clarithromycin ↑ etravirine ↓ clarithromycin ↑ 14-OH-clarithromycin Clarithromycin exposure was decreased by Etravirine; however, concentrations of the active metabolite, 14-hydroxy-clarithromycin, were increased. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antifungals : fluconazole ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (क्लोमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (क्वेटियापिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (ग्वानफेसिन लेबल, दवाओं के इंटरैक्शन)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (ज़ाफिरलुकास्ट लेबल, सावधानियां)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers If co-administration with a potent CYP3A4 inducer is necessary, the patient should be closely monitored and the dose of ZONISAMIDE and other drugs that CYP3A4 substrates may need to be adjusted [see Clinical Pharmacology ( 12.3 )] . (ज़ोनिसामाइड लेबल, दवाओं के इंटरैक्शन)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Use of tiagabine HCl without enzyme-inducing antiepileptic drugs results in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION ). (टियागाबिन लेबल, चेतावनियां)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (टॉरसेमाइड लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (ट्रेप्रोस्टिनिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (डाइवैल्प्रोएक्स (वैल्प्रोएट) लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

A decrease in diazepam dose may be needed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

The serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect. amiodarone bepridil disopyramide flecainide lidocaine (systemic) mexiletine propafenone quinidine ↓ antiarrhythmics Concentrations of these antiarrhythmics may be decreased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance . (डेक्सलैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Systemic dexamethasone should be used with caution or alternatives should be considered, particularly for long-term use. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

…nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir]) /HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]). (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (डॉक्सरकैल्सिफेरॉल लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Monitor for increased dronabinol-related adverse reactions when dronabinol oral solution is co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice). (ड्रोनाबिनोल लेबल, दवाओं के इंटरैक्शन)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (थायोथिक्सीन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (निंटेडानिब लेबल, दवाओं के इंटरैक्शन)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (निमोडिपिन लेबल, चेतावनियां और सावधानियां)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (नेटेग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with esomeprazole magnesium may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

In contrast, significant increases in systemic exposure of the progestin have been noted in cases of co-administration with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine). (नॉरएथिस्टेरोन लेबल, दवाओं के इंटरैक्शन)

…with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritnoavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]). (नॉरएल्जेस्ट्रोमिन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

…immunodeficiency virus (HIV)/Hepatitis C virus (HCV) protease inhibitors, non-nucleoside reverse transcriptase inhibitors , and HIV/AIDS medications containing strong inhibitors or inducers of CYP3A Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease… (नॉरजेस्टिमेट और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

…progestin have been noted when COCs are co-administered with some HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos) amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir], or increase [e.g., indinavir and atazanavir/ritonavir] HCV protease inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]). (नॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. (पैंटोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for itraconazole, ketoconazole or posaconazole may be necessary depending on the other co-administered drugs. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when co-administered with INNOPRAN XL. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (फिडैक्सोमाइसिन लेबल, दवाओं के इंटरैक्शन)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (फेसोटेरोडिन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antifungals : fluconazole ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (बेक्साग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antifungals : fluconazole ↑ etravirine ↔ fluconazole Co-administration of etravirine and fluconazole significantly increased etravirine exposures. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (रक्सोलिटिनिब लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (रिफैक्सिमिन लेबल, चेतावनियां और सावधानियां)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

Effects of Other AEDs on BANZEL Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the clearance of BANZEL (see Table 6). (रुफिनामाइड लेबल, दवाओं के इंटरैक्शन)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. (रैबेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (रैमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

The serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect. amiodarone bepridil disopyramide flecainide lidocaine (systemic) mexiletine propafenone quinidine ↓ antiarrhythmics Concentrations of these antiarrhythmics may be decreased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (लिनाग्लिप्टिन लेबल, दवाओं के इंटरैक्शन)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

In contrast, significant increases in systemic exposure of the estrogen and/or progestin have been noted when CHCs are co-administered with certain other HIV protease inhibitors (e.g., indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (e.g., etravirine). (लेवोनॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. (लैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (लैकोसामाइड लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. (लोपेरामाइड लेबल, दवाओं के इंटरैक्शन)

Benzodiazepine: diazepam ↑ diazepam Concomitant use of Etravirine with diazepam may increase plasma concentrations of diazepam. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

The international normalized ratio (INR) should be monitored when warfarin is combined with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (विलाज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and voriconazole should be co-administered with caution. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustments for these HMG-CoA reductase inhibitors may be necessary. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitors: clopidogrel ↓ clopidogrel (active) metabolite Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CCR5 antagonists maraviroc ↔ etravirine ↓ maraviroc When Etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (सेलेजिलिन लेबल, दवाओं के इंटरैक्शन)

Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticoagulant : warfarin ↑ anticoagulants Warfarin concentrations may be increased when co-administered with Etravirine. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving Etravirine in combination with other HIV-1 antiretroviral agents in an observational study. (एट्राविरिन लेबल, चेतावनियां और सावधानियां)

Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving Etravirine in combination with other HIV-1 antiretroviral agents in an observational study. (एट्राविरिन लेबल, चेतावनियां और सावधानियां)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 such as St. (एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 such as St. (एस्ट्राडियोल और नॉरएथिस्टेरोन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (ग्लिसरॉल फिनाइलब्यूटिरेट लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (डैपाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with MPA Injectable Suspension, USP. (मेड्रोक्सीप्रोजेस्टेरोन लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving Etravirine in combination with other HIV-1 antiretroviral agents in an observational study. (एट्राविरिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (रियोसिगुआट लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving Etravirine in combination with other HIV-1 antiretroviral agents in an observational study. (एट्राविरिन लेबल, चेतावनियां और सावधानियां)

Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving Etravirine in combination with other HIV-1 antiretroviral agents in an observational study. (एट्राविरिन लेबल, चेतावनियां और सावधानियां)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (लोमिटापाइड लेबल, दवाओं के इंटरैक्शन)

Anticonvulsants : carbamazepine phenobarbital phenytoin ↓ etravirine Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (सिलोडोसिन लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended. (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (एसेनापिन लेबल, दवाओं के इंटरैक्शन)

…to the drugs included in Table 4, the interaction between Etravirine and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. (माइकाफंगिन लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

…to the drugs included in Table 4, the interaction between Etravirine and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate. (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)